CervoMed
Most recent annual filing: 2026-03-15
- Neflamapimod RESTORE topline2H 2026Neflamapimod RESTORE topline, 2H 2026, material
- Cash runway guidance update3Q 2027Cash runway guidance update, 3Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
neflamapimod
Small Molecule Target: p38α MAPK, p38α
Discontinued (1)
- neflamapimod — Stroke · enrollment ended — strategic deprioritization
Biotech Distilled coverage (13)
- 2026-08-08 UPDATE: CervoMed (CRVO) — The Going Concern Flag Just Came Down
- 2026-08-05 UPDATE: CervoMed (CRVO) — The UK Just Handed Them a Fast Lane 🔒 Paid
- 2026-07-14 UPDATE: CervoMed (CRVO) — The AAIC Receipts and the 80 mg BID Safety Read
- 2026-06-18 UPDATE: CervoMed (CRVO) — Stopgap #2, A 2042 Patent, and a +71% Tape 🔒 Paid
- 2026-06-15 UPDATE: CervoMed (CRVO) — Same Data, Louder Font
- 2026-06-10 UPDATE: CervoMed (CRVO) - The Bag Got Secured. Sort Of.
- 2026-05-16 UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown
- 2026-04-27 UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized 🔒 Paid
- 2026-03-29 UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth 🔒 Paid
- 2026-03-21 UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen 🔒 Paid
- 2026-03-14 UPDATE: CervoMed (CRVO) – Annual Report Drops 🔒 Paid
- 2026-03-07 UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... 🔒 Paid
- 2025-12-31 CervoMed (CRVO): Scientific Due Diligence for Neflamapimod
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.